

1 **Circulating interleukin-6 levels and incident ischemic stroke: a systematic review**
2 **and meta-analysis of population-based cohort studies**

3 Andreas Papadopoulos, MD¹, Konstantinos Palaiopoulos, MD², Harry Björkbacka, PhD³,
4 Annette Peters, PhD^{4,5,6,7}, James A. de Lemos, MD⁸, Sudha Seshadri, MD^{9,10,11}, Martin
5 Dichgans, MD^{12,13,14}, Marios K. Georgakis, MD, PhD¹²

6 ¹ Department of Radiology, 401 General Military Hospital of Athens, Greece

7 ² National Public Health Organization, Athens, Greece

8 ³ Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden

9 ⁴ Institute of Epidemiology, Helmholtz Zentrum München, German Research Center for
10 Environmental Health, Neuherberg, Germany

11 ⁵ German Center for Diabetes Research (DZD), München-Neuherberg, Neuherberg,
12 Germany

13 ⁶ German Research Center for Cardiovascular Disease (DZHK), Partner site Munich
14 Heart Alliance, Germany

15 ⁷ Institute of Medical Information Sciences, Biometry and Epidemiology, Ludwig-
16 Maximilians-University, Munich, Germany

17 ⁸ Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, TX,
18 USA

19 ⁹ National Heart, Lung, and Blood Institute's and Boston University's Framingham Heart
20 Study, Framingham, MA, USA

21 ¹⁰ Department of Medicine, School of Medicine Boston University School of Medicine,
22 Boston, MA, USA

23 ¹¹ Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of
24 Texas Health Sciences Center, San Antonio, TX, USA

25 ¹² Institute for Stroke and Dementia Research (ISD), University Hospital, Ludwig-
26 Maximilians-University LMU, Munich, Germany

27 ¹³ Munich Cluster for Systems Neurology (SyNergy), Munich, Germany

28 ¹⁴ German Centre for Neurodegenerative Diseases (DZNE), Munich, Germany

29 **Corresponding author:**

30 Marios Georgakis, MD, PhD

31 Neurology resident & Postdoctoral researcher

32 Institute for Stroke and Dementia Research, University Hospital LMU

33 Ludwig-Maximilians-University (LMU), Munich, Germany

34 Feodor-Lynen-Str. 17, 81377 Munich, Germany

35 Telephone: +49-89-4400-46063; Fax: +49-89-4400-46040;

36 e-mail: marios.georgakis@med.uni-muenchen.de

37

38 **Title character count (with spaces):** 135

39 **Word count of abstract:** 250

40 **Word count of main text:** 3,255

41 **Number of tables:** 1

42 **Number of figures:** 4

43 **Supplementary file includes:** 1 Supplementary Table, 2 Supplementary Figures

44 **Additional files:** PRISMA checklist

45 **Search terms:** IL-6; Stroke; Ischemic; Cerebrovascular; Meta-analysis

46 **Disclosures:** None

47 **Funding sources:** HB is supported by the Swedish Research Council and the Swedish
48 Heart-Lung Foundation. The analysis from the Framingham Heart Study has been
49 funded from NHLBI: HHSN 268201500001I and NINDS grant R01 NS017950 (SS). MD
50 is supported by the Deutsche Forschungsgemeinschaft (German Research Foundation)
51 under Germany's Excellence Strategy within the framework of the Munich Cluster for
52 Systems Neurology (EXC 2145 SyNergy – ID 390857198) and as part of CRC 1123
53 (B3) and DI 722/16-1. MKG has received funding from the Onassis Foundation, the
54 German Academic Exchange Service, and the Vascular Dementia Research
55 Foundation.

56 **ABSTRACT**

57 **Objective:** To determine the association between circulating interleukin-6 (IL-6) levels
58 and risk of incident ischemic stroke in the general population. **Methods:** Following the
59 PRISMA guidelines, we systematically searched the literature for population-based
60 prospective cohort studies exploring the association between circulating IL-6 levels and
61 risk of incident ischemic stroke. We pooled association estimates for ischemic stroke
62 risk with random-effect meta-analyses and explored non-linear effects in dose-response
63 meta-analyses. Risk of bias was assessed with the Newcastle-Ottawa scale (NOS).
64 **Results:** We identified 11 studies (n=27,411 individuals; 2,669 incident stroke cases)
65 meeting our eligibility criteria. Overall, quality of the included studies was high (median 8
66 out of 9 NOS points). In meta-analyses, 1-standard deviation increment in circulating IL-
67 6 levels was associated with a 19% increase in risk of incident ischemic stroke over a
68 mean follow-up of 12.4 years (RR 1.19; 95% CI 1.10 to 1.28). A dose-response meta-
69 analysis showed a linear association between circulating IL-6 levels and ischemic stroke
70 risk. There was only moderate heterogeneity and the results were consistent in
71 sensitivity analyses restricted to studies of low risk of bias and studies fully adjusting for
72 demographic and vascular risk factors. The results also remained stable following
73 adjustment for publication bias. **Conclusions:** Higher circulating IL-6 levels in
74 community-dwelling individuals are associated with higher long-term risk of incident
75 ischemic stroke in a linear pattern and independently of conventional vascular risk
76 factors. Along with findings from genetic studies and clinical trials, these results provide
77 additional support for a key role of IL-6 signaling in ischemic stroke.

78 **INTRODUCTION**

79 Stroke is a leading cause of adult disability and mortality worldwide.^{1, 2} Identifying risk
80 factors for stroke is important for developing effective primary and secondary preventive
81 strategies. Inflammation has recently attracted attention as a potential target for
82 lowering ischemic stroke risk.^{3, 4} Data from large-scale trials⁵⁻⁷ have provided proof-of-
83 concept evidence that anti-inflammatory approaches can lower cardiovascular risk. Still,
84 these trials tested combined cardiovascular endpoints and evidence regarding the utility
85 of anti-inflammatory approaches specifically for stroke prevention is scarce.⁸

86 Developing effective anti-inflammatory approaches for stroke prevention would require
87 identifying key inflammatory mediators involved in stroke pathogenesis.^{9, 10} While there
88 is extensive literature regarding association of C-reactive protein levels, a general
89 marker of inflammation, with stroke,¹¹ there is only limited data regarding other
90 inflammatory cytokines. Data from human genetic studies have suggested a potentially
91 causal role of the pro-inflammatory cytokine interleukin-6 (IL-6) in vascular disease,¹²⁻¹⁴
92 thus making it a promising drug target.

93 Moving towards anti-inflammatory treatments specifically targeting IL-6 signaling¹⁵
94 would benefit from clarifying the magnitude and shape of the association between
95 circulating IL-6 levels and ischemic stroke. While prospective cohort studies have
96 established robust associations between circulating IL-6 levels with risk of coronary
97 artery disease,¹⁶ there is only limited evidence regarding associations with ischemic
98 stroke,¹⁷⁻¹⁹ which also entails mechanisms other than atherosclerosis. Here, we set out
99 to leverage data from published literature along with unpublished cohort studies in a
100 systematic review and meta-analysis in order to explore the association of circulating IL-

101 6 levels and risk of incident ischemic stroke in population-based prospective cohort
102 studies.

103

104 **METHODS**

105 This systematic review was conducted according to the Preferred Reporting Items for
106 Systematic Reviews and Meta-Analyses (PRISMA) statement guidelines.²⁰

107

108 **Search strategy**

109 Two independent reviewers (A.P. and K.P.) systematically screened the medical search
110 engine PubMed from inception to March 4, 2021. We searched for cohort studies
111 investigating the association between circulating IL-6 levels and risk of ischemic stroke
112 using a combination of the predefined key words “interleukin-6”, “IL-6”, “stroke”, and
113 “cerebrovascular disease”. Reference lists of eligible articles were hand-searched for
114 possible eligible studies not identified through the primary database search (“snowball”
115 procedure). No language or publication year restrictions were applied. Eligible studies
116 were assessed for potential population overlap according to recruitment period,
117 geographical site, study name, and sample size. In case of overlap, we included the
118 study with the largest number of incident events. We also contacted the corresponding
119 authors of studies, which did not present the desired analysis but presented the
120 required variables, to request for additional data.

121

122 **Eligibility criteria**

123 Eligible studies should be of a prospective cohort design. Case-cohort and nested case-
124 control analyses within prospective cohorts, as well as prospective *post hoc* analyses
125 from randomized clinical trials, were also considered eligible. Case-control and cross-
126 sectional studies, case series, case reports, systematic or narrative reviews, as well as
127 animal and *in vitro* studies were excluded. Eligible studies should be preferably based
128 on the general population. Studies on high-risk populations, such as populations with
129 conventional vascular risk factors (e.g. diabetes mellitus or hypertension), but free of
130 stroke at baseline were also included. Studies including solely individuals with a history
131 of stroke were excluded, as did studies in very specific high-risk populations, such as
132 individuals with advanced chronic kidney disease on hemodialysis.

133 The exposure variable of interest was circulating IL-6 levels quantified in plasma or
134 serum by immunoassay methods. Due to the lack of universally accepted IL-6 normal
135 value range and differences across variable laboratory kits used by individual studies,
136 we analyzed IL-6 in standardized (1-standard deviation (SD) increment) and not
137 absolute values.

138 We included studies that explored associations between circulating IL-6 levels and risk
139 of incident ischemic stroke, defined according to standardized clinical criteria. We
140 excluded studies examining associations with: (i) a combined cardiovascular endpoint
141 also including ischemic stroke, but not providing association estimates for ischemic
142 stroke; (ii) clinically silent brain infarcts; (iii) stroke mortality; (iv) TIAs; (v) recurrent
143 stroke; and (vi) hemorrhagic stroke. Studies examining combined endpoints of ischemic

144 and hemorrhagic stroke or ischemic stroke and TIAs were included on the basis of the
145 fact that the majority of acute cerebrovascular events represent ischemic strokes.^{21, 22}
146 Prospective studies examining ischemic stroke events over follow-up, but not excluding
147 individuals with a history of prevalent stroke at baseline, were also included in our
148 review, as long as such individuals represented the minority (<50%) of the baseline
149 population.

150

151 **Data extraction**

152 A predefined spreadsheet was used to extract the following variables from each eligible
153 study: publication details (author, year), study parameters (geographical origin,
154 recruitment period, design, sample size, follow-up information), demographic population
155 characteristics (age, sex, race), baseline cardiovascular risk factors (body mass index,
156 diabetes mellitus, atrial fibrillation, coronary artery disease, hypertension, smoking
157 status, hypercholesterolemia), IL-6 quantification details (sample, laboratory kit, storage
158 temperature, scale of qualification), ischemic stroke assessment (definition, clinical
159 scales used, imaging modality, number of cases), and statistical analysis details
160 (analysis type, effect estimates, 95% CI, adjusting variables). Where supplementary
161 data were needed, the corresponding author was contacted.

162

163

164

165 **Risk of bias assessment**

166 We evaluated studies for risk of bias using the nine-item cohort subscale of the
167 Newcastle-Ottawa scale.²³ The following criteria were assessed: (i) representativeness
168 of the exposed cohort: a point was awarded when individuals were drawn from the
169 general population and included both males and females; (ii) selection of the non-
170 exposed cohort: a point was awarded when individuals were drawn from the same
171 community as the exposed; (iii) exposure ascertainment: a point was awarded when the
172 blood drawing protocol and the kit used for IL-6 quantification were reported; (iv)
173 outcome presence at start of study: a point was awarded when individuals with a history
174 of ischemic stroke at baseline were excluded from the analysis; (v and vi) two items for
175 comparability: one point was awarded if the study adjusted for age and sex, and a
176 second point was awarded if the study additionally adjusted for conventional vascular
177 risk factors (at least lipids, blood pressure, diabetes, and body mass index); (vii)
178 outcome assessment: a point was awarded when the study presented association
179 estimates specifically for ischemic stroke, excluding TIAs and hemorrhagic strokes, as
180 well as when a clear definition was provided and each event was confirmed by at least a
181 trained physician; (viii) length of follow-up: a point was awarded when the mean or
182 median follow-up of the cohort was >5 years; (ix) adequacy of follow up cohorts: a point
183 was awarded when the attrition rate was lower than <10%.

184

185

186

187 **Statistical analysis**

188 For each eligible study we extracted association estimates and 95%CI between
189 circulating IL-6 levels and incident ischemic stroke. Out of the 11 studies included in our
190 meta-analysis, 8 presented hazard ratios (HR), 2 odds ratios (OR) and 1 relative risks
191 (RR). First, we transformed all estimates and their corresponding 95% CIs to RRs. If
192 ischemic stroke incidence in the examined cohort exceeded 10%, we used validated
193 formulae,²⁴ whereas in studies with <10% incidence, we considered HRs and ORs to be
194 very close to RRs and thus applied no transformation.^{24, 25}

195 Seven out of the 11 studies analyzed 1-SD increment in log-transformed IL-6 levels,
196 whereas the remaining 4 studies presented association estimates across tertiles or
197 quartiles of IL-6. To enable a meta-analysis across all studies, we used the method of
198 generalized least squares for trend estimation of summarized dose-response data to
199 derive association estimates per 1-SD increment in studies presenting analyses in
200 tertiles or quartiles.^{26, 27} Doses across each category were calculated as fitting SD-
201 increases by using the median values of each tertile/quartile projected on a normal
202 distribution.

203 We then performed random-effect meta-analyses of the derived association estimates
204 using the method described by DerSimonian and Laird²⁸ and obtained a pooled RR with
205 95%CI for the risk of incident ischemic stroke per 1-SD increase in IL-6 levels. The
206 presence of heterogeneity was evaluated by the I^2 , calculated via the Cochran Q
207 statistic. We defined low, moderate, and high heterogeneity as an I^2 of <25%, 25% to
208 75%, and >75%, respectively.²⁹

209 To explore the robustness of our findings, we carried out sensitivity analyses restricted
210 to: (i) studies of the general population; (ii) studies not including TIAs as an outcome;
211 (iii) studies exclusively exploring ischemic stroke; (iv) studies excluding individuals with
212 a history of prevalent stroke at baseline; (v) studies providing imaging confirmation (via
213 CT or MRI) for an infarction beyond the clinical definition of ischemic stroke; (vi) studies
214 adjusting their results for demographic and conventional vascular risk factors; (vii)
215 studies additionally adjusting for circulating C-reactive protein levels; and (viii) studies of
216 a follow-up ≥ 5 years; (ix) studies fulfilling at least 8 out of the 9 quality criteria of NOS.
217 We also ran a separate analysis of the seven studies using the High Sensitivity 600
218 Quantikine ELISA kit by R&D Systems for quantifying circulating IL-6 levels to avoid
219 heterogeneity in the effects due to differences in the used kit. Finally, to exclude
220 potential outlier effects of individual studies, a “leave-one-out” sensitivity analysis was
221 performed.

222 Furthermore, we sought to examine whether circulating IL-6 levels follow a linear
223 association with the risk of incident ischemic stroke. We used multivariate random-effect
224 meta-analysis and constructed a double-tail restricted three-cubic knot (10%, 50%,
225 90%) flexible model, which demonstrates the actual shape of the relationship between
226 the RR for incident ischemic stroke plotted against IL-6 percentiles.³⁰

227 The effect of potential publication bias (small-study effects) was explored using the
228 Egger’s test.³¹ In cases of evidence of small-study effects ($P > 0.10$), we further adjusted
229 the pooled effect estimate for publication bias using a “trim and fill” analysis.³² The
230 results were graphically presented with a funnel plot.

231 All analyses were conducted with the STATA Software, version 16.1 (Stata Corporation,
232 College Station, TX, USA).

233

234 **Data availability**

235 Data not provided in the article due to space limitations will be made available upon
236 reasonable request to the corresponding author.

237

238 **RESULTS**

239 **Review of literature**

240 **Figure 1** summarizes the study selection process. Following an initial screening of
241 2,702 articles yielded by the literature search, we identified 8 articles,^{17-19, 33-36} referring
242 to 11 individual studies (n=27,411), meeting our eligibility criteria. Four of the included
243 studies (DHS, FHS-offspring, MONICA/KORA and MDCS-CV) have not published
244 results on the associations between circulating IL-6 levels and risk of ischemic stroke,
245 but the respective data were provided as part of secondary analysis in a recent meta-
246 analysis focusing on the association of monocyte chemoattractant protein-1 and
247 stroke.³⁷ Association estimates from the latter meta-analysis were used for the purposes
248 of the current study.

249

250

251 **Descriptive study characteristics and risk of bias assessment**

252 Summarized descriptive characteristics of the 11 included studies are presented in
253 **Table 1** and in **Supplementary Table 1**. Mean age of all individuals was 60.5 years
254 (study range, 44.0 to 75.9 years) and 54.8% of the study participants were females.
255 Mean duration of follow-up was 12.4 years (study range, 3.2 to 20.0). All included
256 studies followed a prospective study design: seven of them (n=21,384) featured a
257 cohort study design, while the remaining 4 studies presented either case-cohort (k=2,
258 n=3,425) or nested case-control (k=2, n=2,602) analyses within larger cohorts. Nine of
259 the studies (n=26,149) were based on general population individuals, while 2 (n=1,262;
260 OSAKA and PROSPER) were restricted to high-risk individuals with at least one
261 established vascular risk factor. IL-6 measurements were made on blood drawn at
262 baseline (stored at -70 to -80° C until analyzed). Four studies (n=7,813) used serum and
263 4 (n=10,813) used plasma samples to quantify IL-6, whereas the exact sample was not
264 reported in 3 studies. The kit most commonly used for IL-6 measurements was the High
265 Sensitivity 600 Quantikine ELISA by R&D Systems (7 studies; n=16,918). In 9 studies,
266 where this was reported, intra- and inter-assay coefficients of variation were $\leq 10\%$.

267 Regarding outcome assessment, 9 studies (n=25,244) excluded patients with a history
268 of stroke at baseline and 8 studies (n=18,105) specifically addressed ischemic stroke as
269 their outcome excluding patients with hemorrhagic stroke or TIA. All endpoints were
270 validated by at least two trained physicians, who reviewed each patient's medical or
271 autopsy files. Only 4 studies (n=4,436) explicitly required imaging confirmation of an
272 infarction with CT and/or MRI, as definition of ischemic stroke.

273 The overall study quality was high, with 5 of the studies (45.5%) fulfilling all 9 criteria of
274 the Newcastle-Ottawa scale criteria a (**Table 1**). The median quality score was 8 out of
275 9 (IQR 2, range 3 to 9). The items “representativeness of the exposed cohort”, “outcome
276 not present at start of study”, “assessment of outcome” and “length of follow-up”
277 accounted for most non-awarded points. All studies controlled for age, sex (if
278 applicable) and race (if applicable) and all but one of the studies additionally controlled
279 for conventional vascular risk factors.

280

281 **Circulating IL-6 and risk of incident ischemic stroke**

282 In the meta-analysis of the 11 studies, we found a 1-SD increment in circulating IL-6
283 levels at baseline to be associated with a 19% higher risk of incident ischemic stroke
284 over a mean follow-up of 12.4 years (RR 1.19; 95% CI 1.10 to 1.28; 27,411 individuals;
285 2,669 events, **Figure 2**). The results remained stable in sensitivity analyses for studies
286 excluding individuals with history of prevalent stroke at baseline, studies focusing on
287 incident ischemic stroke explicitly excluding cases of TIA and hemorrhagic stroke, as
288 well as studies requiring imaging confirmation of an infarction (**Figure 3**). Furthermore,
289 our analyses revealed that controlling for conventional vascular risk factors yielded the
290 same pooled association estimate as our main analysis. Further adjustment for high-
291 sensitivity CRP levels led to an anticipated attenuation of the association estimate, as
292 CRP is downstream of IL-6,¹⁵ but the association remained statistically significant.
293 Similar results were also obtained in a sensitivity analysis restricted to studies of low
294 risk of bias (scoring at least 8 out of 9 in NOS). Restricting our analyses to studies

295 quantifying IL-6 with the most commonly used High Sensitivity 600 Quantikine ELISA kit
296 did not change the result. Of note, pooling a set of 6 studies of stroke-free individuals in
297 the general population that specifically examined over a follow-up of ≥ 5 with years
298 associations with incident ischemic stroke (excluding TIAs and hemorrhagic strokes)
299 and further adjusted for conventional vascular risk factors on top of age, sex and race
300 yielded similar results (RR 1.16; 95% CI 1.07 to 1.25; 6 studies; 15,938 individuals;
301 2,029 events). Finally, in “leave-one-out” sensitivity analyses, we found no evidence that
302 any single study significantly influenced the results of our main analysis
303 (**Supplementary Figure 1**).

304 There was only moderate heterogeneity in the main analysis ($I^2=44.6\%$, $p=0.05$; **Figure**
305 **2**), which was not entirely resolved in any of the sensitivity analyses (**Figure 3**). The
306 funnel plot for our main analysis is presented in **Supplementary Figure 2**. Although the
307 Egger’s test detected small-study effects ($P=0.03$) indicating potential presence of
308 publication bias, the association between circulating IL-6 levels and incident ischemic
309 stroke remained stable (RR 1.14; 95% CI 1.05 to 1.24) after correcting our analysis for
310 small-study effects with the “trim and fill” method.

311 As a final step, we aimed to explore the shape of the association between circulating IL-
312 6 levels and risk of incident ischemic stroke. In a dose-response meta-analysis including
313 data from 5 studies (13,385 individuals; 1,831 events), we found a linear relationship
314 between circulating IL-6 levels and incident ischemic stroke (p for non-linearity: 0.52;
315 **Figure 4**).

316

317 **DISCUSSION**

318 Pooling data from 11 population-based prospective cohort studies involving 27,411
319 individuals and 2,669 stroke events, we found higher circulating IL-6 levels at baseline
320 to be associated with a higher risk of incident ischemic stroke over a mean follow-up of
321 12.4 years. IL-6 levels showed a linear relationship with the risk of ischemic stroke
322 following a dose-response pattern. Overall, the study quality was high and the results
323 were stable in sensitivity analyses, as well as when correcting for publication bias.

324 Our meta-analysis extends previous data related to the associations between circulating
325 IL-6 levels with acute coronary events and other vascular phenotypes¹⁶ to ischemic
326 stroke. IL-6 signaling has been demonstrated as one of the most promising targets for
327 anti-inflammatory approaches in cardiovascular disease. The CANTOS trial tested
328 canakinumab, a monoclonal antibody against IL-1b, which is upstream to IL-6, in
329 patients with a recent myocardial infarction and showed a beneficial effects against a
330 combined cardiovascular endpoint, also involving stroke.⁵ Interestingly, secondary
331 analyses from CANTOS showed that the benefit was restricted to individuals in whom
332 canakinumab resulted in meaningful reductions in IL-6 levels.³⁸ Still, CANTOS could not
333 specifically show benefit against stroke,⁵ possibly as a result of limited power. The
334 results from the current meta-analysis, when seen together with Mendelian
335 randomization results supporting associations between lifetime genetically
336 downregulated IL-6 signaling and lower ischemic stroke risk¹³ provide further support in
337 favor of IL-6 signaling as a promising target for lowering stroke risk.

338 An interesting finding from our analysis is the clearly log-linear dose-response
339 relationship between IL-6 levels and stroke risk. Our results indicate an approximately
340 19% increment in risk of ischemic stroke per-SD increment in log-IL-6 levels. This
341 magnitude of effect, along with the clear dose-response pattern, is comparable to the
342 magnitude and shape of associations that have been reported for non-HDL cholesterol
343 levels (12%, 95%CI: 4-20%),³⁹ and systolic blood pressure (24%, 95%CI: 15-35%),⁴⁰
344 both key therapeutic targets for lowering ischemic stroke risk. While this association
345 estimate slightly reduced after correcting for publication bias, it still remained in the
346 same order of magnitude (RR 1.14), thus supporting a meaningful association with the
347 risk of ischemic stroke.

348 Our results should be viewed in the context of specific methodological strengths. First,
349 this meta-analysis is clearly based on prospective cohort population-based studies with
350 relatively long follow-up period, thus precluding the possibility of reverse causation.
351 Furthermore, our rigorous search of published literature, allowed us to pool a large
352 sample size including more than 2,600 incident stroke cases, thus offering the power to
353 explore interesting aspects of this association, such as its robustness against specific
354 forms of bias in sensitivity analyses, and dose-response relationships. Finally, as
355 observed in our risk of bias analysis, the quality of the included studies was generally
356 high, thus further supporting to the validity of the results.

357 Our study also has limitations. There was moderate heterogeneity in the main analysis
358 ($I^2=45\%$), which points to key methodological differences between individual studies.
359 Specifically, while all of the studies had a prospective study design, some of them
360 applied case-cohort or nested case-control approaches within the larger cohorts.

361 Furthermore, there were wide differences with regards to mean follow-up intervals
362 ranging from 3 to 20 years across studies. Similarly, there were between-study
363 differences regarding the definition of the outcomes, with some of the studies focusing
364 only on stroke as a whole and not ischemic stroke, whereas other studies also included
365 transient ischemic attacks. Still, it should be mentioned that the results were stable in all
366 sensitivity analyses, even the one focusing on imaging-confirmed infarctions. Another
367 source of heterogeneity is the method used for measuring IL-6 levels, for which, as
368 opposed to high-sensitivity CRP, there are no standard clinical platforms for
369 quantification. To address this issue, we performed all our analyses based on
370 standardized IL-6 levels, but still differences between studies might persist and might
371 affect the results, especially those from the dose-response meta-analysis. Finally, there
372 was evidence of small-study effects indicating publication bias in our analysis, but the
373 results were stable after correcting for it with the trim and fill method.

374 In summary, as illustrated in our meta-analyses, data from observational studies
375 support a clear dose-response association between circulating IL-6 levels and risk of
376 incident ischemic stroke among stroke-free individuals at baseline. While these results
377 cannot establish causality, when triangulated with evidence from human genetic data,
378 as well as indirect evidence from clinical trials, they provide further support for IL-6
379 signaling as a promising target for lowering the risk of ischemic stroke.

380 **Appendix 1: Authors**

Name	Location	Contribution
Andreas Papadopoulos, MD	General Military Hospital of Athens, Greece	data acquisition, analysis, and interpretation of data; statistical analysis; drafting of the manuscript
Konstantinos Palaiopanos, MD	National Public Health Organization, Athens, Greece	data acquisition, analysis, and interpretation of data; drafting of the manuscript
Harry Björkbacka, PhD	Lund University, Malmö, Sweden	data acquisition; critical revision of the manuscript for intellectual content; study supervision
Annette Peters, PhD	Helmholtz Zentrum München, Germany	data acquisition; critical revision of the manuscript for intellectual content; study supervision
James A. de Lemos, MD	University of Texas Southwestern Medical Center, Dallas, TX, USA	data acquisition; critical revision of the manuscript for intellectual content; study supervision
Sudha Seshadri, MD	University of Texas Health Sciences Center, San Antonio, TX, USA	data acquisition; critical revision of the manuscript for intellectual content; study supervision
Martin Dichgans, MD	LMU Munich, Germany	interpretation of data; critical revision of the manuscript for intellectual content; study supervision
Marios K. Georgakis, MD, PhD	LMU Munich, Germany	concept and design; data acquisition, analysis, and interpretation of data; drafting of the manuscript; critical revision of the manuscript for intellectual content; study supervision

381 **REFERENCES**

- 382 1. GBD-2017-Collaborators. Global, regional, and national age-sex-specific
383 mortality for 282 causes of death in 195 countries and territories, 1980-2017: a
384 systematic analysis for the Global Burden of Disease Study 2017. *Lancet*
385 2018;392:1736-1788.
- 386 2. GBD-2019-Collaborators. Global burden of 369 diseases and injuries in 204
387 countries and territories, 1990-2019: a systematic analysis for the Global Burden of
388 Disease Study 2019. *Lancet* 2020;396:1204-1222.
- 389 3. Esenwa CC, Elkind MS. Inflammatory risk factors, biomarkers and associated
390 therapy in ischaemic stroke. *Nat Rev Neurol* 2016;12:594-604.
- 391 4. Libby P, Ridker PM, Hansson GK, Leducq Transatlantic Network on
392 Atherothrombosis. Inflammation in atherosclerosis: from pathophysiology to practice. *J*
393 *Am Coll Cardiol* 2009;54:2129-2138.
- 394 5. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with
395 Canakinumab for Atherosclerotic Disease. *N Engl J Med* 2017;377:1119-1131.
- 396 6. Tardif JC, Kouz S, Waters DD, et al. Efficacy and Safety of Low-Dose Colchicine
397 after Myocardial Infarction. *N Engl J Med* 2019;381:2497-2505.

- 398 7. Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in Patients with Chronic
399 Coronary Disease. *N Engl J Med* 2020;383:1838-1847.
- 400 8. Katsanos AH, Palaiodimou L, Price C, et al. Colchicine for stroke prevention in
401 patients with coronary artery disease: a systematic review and meta-analysis. *Eur J*
402 *Neurol* 2020;27:1035-1038.
- 403 9. Kelly PJ, Murphy S, Coveney S, et al. Anti-inflammatory approaches to
404 ischaemic stroke prevention. *J Neurol Neurosurg Psychiatry* 2018;89:211-218.
- 405 10. Georgakis MK, Gill D, Rannikmäe K, et al. Genetically Determined Levels of
406 Circulating Cytokines and Risk of Stroke. *Circulation* 2019;139:256-268.
- 407 11. Kaptoge S, Di Angelantonio E, Lowe G, et al. C-reactive protein concentration
408 and risk of coronary heart disease, stroke, and mortality: an individual participant meta-
409 analysis. *Lancet* 2010;375:132-140.
- 410 12. Swerdlow DI, Holmes MV, Kuchenbaecker KB, et al. The interleukin-6 receptor
411 as a target for prevention of coronary heart disease: a mendelian randomisation
412 analysis. *Lancet* 2012;379:1214-1224.
- 413 13. Georgakis MK, Malik R, Gill D, Franceschini N, Sudlow CLM, Dichgans M.
414 Interleukin-6 Signaling Effects on Ischemic Stroke and Other Cardiovascular Outcomes:
415 A Mendelian Randomization Study. *Circ Genom Precis Med* 2020;13:e002872.

- 416 14. Georgakis MK, Malik R, Li X, et al. Genetically downregulated interleukin-6
417 signaling is associated with a favorable cardiometabolic profile: a phenome-wide
418 association study. *Circulation* 2021 (in press):2020.2010.2028.20220822.
- 419 15. Ridker PM. From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving
420 Upstream To Identify Novel Targets for Atheroprotection. *Circ Res* 2016;118:145-156.
- 421 16. Kaptoge S, Seshasai SR, Gao P, et al. Inflammatory cytokines and risk of
422 coronary heart disease: new prospective study and updated meta-analysis. *Eur Heart J*
423 2014;35:578-589.
- 424 17. Jenny NS, Callas PW, Judd SE, et al. Inflammatory cytokines and ischemic
425 stroke risk: The REGARDS cohort. *Neurology* 2019;92:e2375-e2384.
- 426 18. Kaplan RC, McGinn AP, Baird AE, et al. Inflammation and hemostasis
427 biomarkers for predicting stroke in postmenopausal women: the Women's Health
428 Initiative Observational Study. *J Stroke Cerebrovasc Dis* 2008;17:344-355.
- 429 19. Patterson CC, Smith AE, Yarnell JW, Rumley A, Ben-Shlomo Y, Lowe GD. The
430 associations of interleukin-6 (IL-6) and downstream inflammatory markers with risk of
431 cardiovascular disease: the Caerphilly Study. *Atherosclerosis* 2010;209:551-557.

- 432 20. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting
433 systematic reviews and meta-analyses of studies that evaluate healthcare interventions:
434 explanation and elaboration. *Bmj* 2009;339:b2700.
- 435 21. O'Donnell MJ, Xavier D, Liu L, et al. Risk factors for ischaemic and intracerebral
436 haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study.
437 *Lancet* 2010;376:112-123.
- 438 22. Rothwell PM, Coull AJ, Silver LE, et al. Population-based study of event-rate,
439 incidence, case fatality, and mortality for all acute vascular events in all arterial
440 territories (Oxford Vascular Study). *Lancet* 2005;366:1773-1783.
- 441 23. Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The
442 newcastle-ottawa scale (nos) for assessing the quality if nonrandomized studies in
443 meta-analyses. 2011, available at
444 http://www.Ohri.Ca/programs/clinical_epidemiology/oxford.Asp, accessed January 20,
445 2021. [online].
- 446 24. VanderWeele TJ. Optimal approximate conversions of odds ratios and hazard
447 ratios to risk ratios. *Biometrics* 2020;76:746-752.
- 448 25. McNutt LA, Wu C, Xue X, Hafner JP. Estimating the relative risk in cohort studies
449 and clinical trials of common outcomes. *Am J Epidemiol* 2003;157:940-943.

- 450 26. Greenland S, Longnecker MP. Methods for trend estimation from summarized
451 dose-response data, with applications to meta-analysis. *Am J Epidemiol*
452 1992;135:1301-1309.
- 453 27. Orsini N, Li R, Wolk A, Khudyakov P, Spiegelman D. Meta-analysis for linear and
454 nonlinear dose-response relations: examples, an evaluation of approximations, and
455 software. *Am J Epidemiol* 2012;175:66-73.
- 456 28. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials*
457 1986;7:177-188.
- 458 29. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in
459 meta-analyses. *Bmj* 2003;327:557-560.
- 460 30. White IR. Multivariate Random-effects Meta-regression: Updates to Mvmeta. *The*
461 *Stata Journal* 2011;11:255-270.
- 462 31. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected
463 by a simple, graphical test. *Bmj* 1997;315:629-634.
- 464 32. Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing
465 and adjusting for publication bias in meta-analysis. *Biometrics* 2000;56:455-463.

- 466 33. Cainzos-Achirica M, Enjuanes C, Greenland P, et al. The prognostic value of
467 interleukin 6 in multiple chronic diseases and all-cause death: The Multi-Ethnic Study of
468 Atherosclerosis (MESA). *Atherosclerosis* 2018;278:217-225.
- 469 34. Cesari M, Penninx BW, Newman AB, et al. Inflammatory markers and onset of
470 cardiovascular events: results from the Health ABC study. *Circulation* 2003;108:2317-
471 2322.
- 472 35. Miwa K, Tanaka M, Okazaki S, et al. Association between interleukin-6 levels
473 and first-ever cerebrovascular events in patients with vascular risk factors. *Arterioscler
474 Thromb Vasc Biol* 2013;33:400-405.
- 475 36. Stott DJ, Welsh P, Rumley A, et al. Adipocytokines and risk of stroke in older
476 people: a nested case-control study. *Int J Epidemiol* 2009;38:253-261.
- 477 37. Georgakis MK, Malik R, Björkbacka H, et al. Circulating Monocyte
478 Chemoattractant Protein-1 and Risk of Stroke: Meta-Analysis of Population-Based
479 Studies Involving 17□180 Individuals. *Circ Res* 2019;125:773-782.
- 480 38. Ridker PM, Libby P, MacFadyen JG, et al. Modulation of the interleukin-6
481 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality:
482 analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study
483 (CANTOS). *Eur Heart J* 2018;39:3499-3507.

484 39. Di Angelantonio E, Sarwar N, Perry P, et al. Major lipids, apolipoproteins, and
485 risk of vascular disease. *Jama* 2009;302:1993-2000.

486 40. Psaty BM, Furberg CD, Kuller LH, et al. Association between blood pressure
487 level and the risk of myocardial infarction, stroke, and total mortality: the cardiovascular
488 health study. *Arch Intern Med* 2001;161:1183-1192.

489 **Table 1. Descriptive characteristics of the included studies.** Characteristics of studies investigating the association between
 490 circulating blood IL-6 values and prospective stroke.

Cohort	MESA	HealthABC	REGARDS	HaBPS	Osaka	Caerphilly	PROSPER	DHS	FHS-offspring	MONICA/KORA	MDCS-CV
Geographic setting (recruitment years)	US (2000-2002)	US (1997-1998)	US (2003-2007)	US (1993-1998)	Japan (2001-2009)	Wales, UK (1984-1988)	Scotland, Ireland, Netherlands (1997-1999)	US (2000-2002)	US (1998-2001)	Germany (1984-2002)	Sweden (1991-1994)
Individuals included in the analysis, n	6,617	2,225	1,370	1,804	464	1,369	798	2,931	3,069	2,055	4,709
Follow-up, y	13.2 (12.7-13.7)	3.6 (0.9)	5.4 (2.2)	6.2 (2.6)	4.8 (2.6)	13.4 (10.1-14.8)	3.2	11.0 (1.7)	13.8 (3.7)	15.7 (6.4)	19.5 (4.9)
Ischemic stroke events, n	298*	60†	503	892	25*	78	179	42	141	99	352
Age, y	62.2 (10.2)	74.1 (2.8)	66.6 (9.3)	68.5 (6.6)	68.8 (8.6)	56.8 (4.6)	75.9 (3.6)	44.0 (10.0)	61.6 (9.4)	52.4 (10.3)	57.5 (4.9)
Female sex, n	3,501 (52.9)	1,234 (55.5)	718 (52.4)	1,804 (100.0)	237 (51.0)	0 (0.0)	393 (29.2)	1,677 (57.2)	1,648 (53.7)	962 (46.8)	2,836 (60.2)
BMI, kg/m ²	28.3 (5.5)	27.4 (4.9)	29.1 (5.9)	27.3 (5.6)	23.1 (3.1)	26.4 (3.6)	26.7 (4.0)	29.7 (7.0)	28.1 (5.3)	27.2 (4.1)	25.6 (3.9)
Diabetes mellitus, n	829 (12.5)	288 (12.9)	373 (27.2)	226 (12.5)	79 (17.0)	43 (3.1)	108 (13.5)	296 (10.1)	379 (12.3)	103 (5.0)	183 (3.9)
CAD, n	0 (0.0)	0 (0.0)	290 (21.2)	133 (7.4)	0 (0.0)	NR	237 (29.7)	79 (2.7)	265 (8.6)	46 (2.2)	78 (1.7)
Hypertension, n	2,184 (33.0) [‡]	1,266 (56.9)	926 (67.6)	970 (53.8)	316 (68.0)	NR	484 (60.7)	944 (32.7)	1,378 (44.9)	877 (42.7)	2,958 (62.8)
SBP, mm Hg	126.6 (21.5)	NR	129.2 (17.2)	133.6 (19.0)	134.9 (17.0)	145.5 (22.3)	155.7 (22.5)	124 (19)	127 (19)	133 (19)	141 (19)
DBP, mm Hg	NR	NR	NR	74.8 (9.8)	77.3 (11.5)	84.2 (12.1)	84.2 (11.4)	78 (10)	74 (10)	82 (11)	87 (9)
Hypercholesterolemia, n	1,069 (16.2) [‡]	204 (9.2) [‡]	462 (33.7) [‡]	309 (17.1) [‡]	246 (53.0)	NR	405 (50.8) [‡]	377 (12.9)	1,615 (52.6)	1,251 (57.4)	2,918 (62.8)
LDL-C, mg/dL	NR	122.9 (34.5)	113 (34.1)	139.9 (37.1)	122.9 (30.9)	NR	NR	107.4 (35.3)	119.9 (32.7)	148.5 (32.4)	161.3 (37.9)
Current smokers, n	849 (12.8)	225 (10.1)	208 (15.2)	108 (6.0)	70 (15.0)	596 (43.5)	204 (25.6)	796 (27.2)	388 (12.6)	517 (25.1)	1,010 (21.5)
Study quality [§]	8 out of 9	7 out of 9	9 out of 9	8 out of 9	7 out of 9	7 out of 9	3 out of 9	9 out of 9	9 out of 9	9 out of 9	9 out of 9
Selection items	★★★★	★★★★	★★★★	☆★★★★	☆★★★★	☆★★★★	☆☆☆☆	★★★★	★★★★	★★★★	★★★★
Comparability items	★★	★★	★★	★★	★★	★★	★☆	★★	★★	★★	★★
Outcome items	☆☆★	☆☆★	★★★	★★★	☆☆★	★★★	★☆☆	★★★	★★★	★★★	★★★

491 Values are n (%), mean (SD) or median (25th-75th).

492 NR = not reported; BMI = body mass index; CAD = coronary artery disease; SBP = systolic blood pressure; DBP = diastolic blood pressure; LDL-C = low-density lipoprotein cholesterol.

493 * Refers to total stroke cases (ischemic + hemorrhagic). † Refers to total stroke cases (ischemic + hemorrhagic) and TIAs. ‡ individuals under anti-hypertensive or lipid-lowering medication(s).

494 § Selection items include: representativeness of the exposed cohort, selection of the non-exposed cohort, ascertainment of exposure, and exclusion of outcome presence at start of study;

495 comparability items include: comparability for age, sex, race and comparability for vascular risk factors; outcome items include: assessment of outcome, length of follow-up, and adequacy of follow-up cohorts. The items are scored in the order mentioned; a filled star symbol indicates that the study is awarded a point at the respective criterion.

491
492
493
494
495
496

497 **FIGURE TITLES AND LEGENDS**

498 **Figure 1. Flowchart of the study selection process.** Steps and number of articles
499 screened per step during the study selection process.

500 CVE = cardio-vascular events.

501 **Figure 2. Meta-analysis of the association between circulating IL-6 levels (1-SD**
502 **increment) and risk of incident ischemic stroke.** Risk Ratios (RR) of each study
503 are depicted as data markers; black boxes around the data markers indicate the
504 statistical weight of the respective study; 95% CIs are indicated by the black error
505 bars; pooled-effect estimate along with its 95% CI is reflected as a black diamond.

506 **Figure 3. Sensitivity analyses of the association between circulating IL-6 levels**
507 **(1-SD increment) and risk of incident ischemic stroke.** Pooled random-effect
508 Risk Ratios (RR) of each analysis are presented as green data markers; 95% CIs
509 are indicated by the black error bars; the vertical green dashed line indicates the
510 overall effect estimate of the main analysis.

511 * High Sensitivity 600 Quantikine ELISA by R&D Systems.

512 ELISA = enzyme-linked immunosorbent assay; CRP, C-reactive protein; NOS =
513 Newcastle - Ottawa scale.

514 **Figure 4. Dose-response meta-analysis of the association between circulating**
515 **IL-6 levels (standardized values in percentiles) and risk of incident ischemic**
516 **stroke.** A double-tail restricted, 3 cubic knot (10%, 50%, 90%) flexible model was
517 used. IL-6 values have been projected on a normal distribution and are presented as
518 percentiles. The median of the 1st quartile (12.5th percentile) is used as the
519 reference. The analysis is based on 5 studies (13,385 individuals; 1,831 stroke
520 cases).







